Clinical characteristics of subjects
| . | Subject no. 1 . | Subject no. 2 . | Subject no. 3 . |
|---|---|---|---|
| Age, y | 49 | 31 | 61 |
| Sex | F | F | F |
| Weight, kg | 92 | 84 | 54 |
| Prior autoimmune disorders | No | No | Yes |
| Number of PEG-rHuMGDF doses | 3 | 2 | 28 |
| Total dose of PEG-rHuMGDF, μg | 828 | 504 | 7602 |
| Pretreatment platelet count, × 109/L | 219 | 288 | 246 |
| Minimal platelet count, × 109/L | 6 | 9 | 2 |
| HLA | |||
| Class I | |||
| HLA-A | 11, 24 | 2, 3 | nt |
| HLA-B | 60, 62(w6) | 61, 62(w6) | nt |
| HLA-C | w3, w6 | w3, w- | nt |
| Class II | |||
| HLA-DQB5 | 0302/7, - | 0302/7, 0602/11 | nt |
| HLA-DR B1 | 04, - | 04, 15 | nt |
| HLA-DR B3 | nt | ||
| HLA-DR B4 | 01 | 01 | nt |
| HLA-DR B5 | 0101 | nt | |
| Platelet type | |||
| HPA-1 | a/a | a/a | nt |
| HPA-3 | a/a | a/b | nt |
| HPA-5 | a/b | b/b | nt |
| Antiplatelet antibody* | |||
| IIF | 4+ | Negative | nt |
| ACE | Negative | Negative | nt |
| ACE II | Negative | Negative | nt |
| MACE | Negative | Negative | nt |
| Anti-TPO IgG, % of total IgG† | |||
| IgG1 (normal = 65%) | 78 | nt | 1 |
| IgG2 (normal = 23%) | 4 | nt | 27 |
| IgG3 (normal = 8%) | 0 | nt | 14 |
| IgG4 (normal = 4%) | 18 | nt | 58 |
| TPO cDNA sequence | Normal | Normal | nt |
| . | Subject no. 1 . | Subject no. 2 . | Subject no. 3 . |
|---|---|---|---|
| Age, y | 49 | 31 | 61 |
| Sex | F | F | F |
| Weight, kg | 92 | 84 | 54 |
| Prior autoimmune disorders | No | No | Yes |
| Number of PEG-rHuMGDF doses | 3 | 2 | 28 |
| Total dose of PEG-rHuMGDF, μg | 828 | 504 | 7602 |
| Pretreatment platelet count, × 109/L | 219 | 288 | 246 |
| Minimal platelet count, × 109/L | 6 | 9 | 2 |
| HLA | |||
| Class I | |||
| HLA-A | 11, 24 | 2, 3 | nt |
| HLA-B | 60, 62(w6) | 61, 62(w6) | nt |
| HLA-C | w3, w6 | w3, w- | nt |
| Class II | |||
| HLA-DQB5 | 0302/7, - | 0302/7, 0602/11 | nt |
| HLA-DR B1 | 04, - | 04, 15 | nt |
| HLA-DR B3 | nt | ||
| HLA-DR B4 | 01 | 01 | nt |
| HLA-DR B5 | 0101 | nt | |
| Platelet type | |||
| HPA-1 | a/a | a/a | nt |
| HPA-3 | a/a | a/b | nt |
| HPA-5 | a/b | b/b | nt |
| Antiplatelet antibody* | |||
| IIF | 4+ | Negative | nt |
| ACE | Negative | Negative | nt |
| ACE II | Negative | Negative | nt |
| MACE | Negative | Negative | nt |
| Anti-TPO IgG, % of total IgG† | |||
| IgG1 (normal = 65%) | 78 | nt | 1 |
| IgG2 (normal = 23%) | 4 | nt | 27 |
| IgG3 (normal = 8%) | 0 | nt | 14 |
| IgG4 (normal = 4%) | 18 | nt | 58 |
| TPO cDNA sequence | Normal | Normal | nt |